By Connor Hart
Jacobs Solutions disclosed post-closing adjustments stemming from a transaction it completed with Amentum last year. The Dallas company received $70 million and the right to receive nearly 7.3 million shares of Amentum's common stock. Jacobs used the money to repay a portion of debt and plans to distribute Amentum's stock to its shareholders. Shares up 6.9%, to $122.80, in after-hours trading.
Argenx received approval from the Food and Drug Administration for a new delivery method of its treatment for certain patients with a rare autoimmune disease. The approval of the treatment, Vyvgart Hytrulo, in a prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalence to the treatment in a vial, the immunology company said. The prefilled syringe is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver or healthcare professional. American depositary receipts rise 6.2%, to $580, in post-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 10, 2025 19:29 ET (23:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。